Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
None
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in patients with

adenocarcinoma of colon
platelet count
adjuvant chemotherapy
oxaliplatin
adenocarcinoma
  • 5 views
  • 07 Nov, 2020
  • 1 location
None
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

-vascular drugs have synergistic effects is worth studying. This study is a phase II prospective clinical study of PD-1 inhibitor combined with bevacizumab and FOLFIRI regimen in the second-line treatment

  • 0 views
  • 12 Sep, 2021
  • 1 location
None
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to receive FOLFIRI or CAPTEM as second line treatment. Disease control rate (DCR) and safety are primary objectives, secondary objectives are Disease …

line of therapy
temozolomide
ki-67
everolimus
carboplatin
  • 28 views
  • 07 Mar, 2021
  • 23 locations
None
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

This trial aims to evaluate the efficacy, safety of high-dose FOLFIRI regimen in advanced colorectal cancer patients with wild-type UGT1A1*6 and *28.

adenocarcinoma
metastasis
liver metastasis
irinotecan
neutrophil count
  • 0 views
  • 23 Jan, 2021
  • 1 location
None
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

From 100 colorectal cancer patients being treated with FOLFIRI regimen or any kind of irinotecan containing regimen, blood samples for irinotecan and its metabolites levels and genotypes

measurable disease
irinotecan
fluoropyrimidine
folfiri regimen
metastatic colorectal cancer
  • 6 views
  • 07 Nov, 2020
  • 1 location
None
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel

  • 12 views
  • 01 Oct, 2021
  • 446 locations
None
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

Bevacizumab, an antibody against vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens has been approved in the 1st and 2nd line treatments for metastatic colorectal cancers(mCRC). Other inhibitors of the VEGF pathway, such as Ramucirumab and Aflibercept are also approved in the 2nd line therapy. Apatinib is …

capecitabine
growth factor
folfox regimen
metastatic colorectal cancer
adenocarcinoma
  • 0 views
  • 04 Oct, 2021
  • 1 location
None
Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.

modified folfirinox regimen
folfirinox
maintenance therapy
pdac
induction chemotherapy
  • 8 views
  • 24 Jan, 2021
  • 33 locations
None
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept Irinotecan (Day 1 or Day 1 3) 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.

metastatic colorectal cancer
metastasis
EGFR
irinotecan
leucovorin
  • 0 views
  • 02 Sep, 2021
  • 1 location
None
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Bevacizumab, as an antibody of vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens for metastatic colorectal cancer, has become the classical first-line treatment. However, vast majority of patients eventually will suffer progression disease. The second-line treatment includes replacing chemotherapy regimens whistle continuing bevacizumab or other anti-VEGF antibodies, …

  • 0 views
  • 22 Jan, 2021
  • 1 location